

# Cã;rmen BrÃ;s-Silva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7912187/publications.pdf>

Version: 2024-02-01

48  
papers

1,019  
citations

471509

17  
h-index

501196

28  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1593  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis. , 2006, 111, 508-531.		155
2	<i>Bmpr2</i> Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 932-948.	1.6	74
3	Cardiotoxicidade associada À terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 395-409.	0.5	62
4	Rodent models of heart failure: an updated review. <i>Heart Failure Reviews</i> , 2013, 18, 219-249.	3.9	62
5	Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H1587-H1594.	3.2	57
6	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , 2018, 114, 880-893.	3.8	52
7	Therapeutic potential of neuregulin-1 in cardiovascular disease. <i>Drug Discovery Today</i> , 2013, 18, 836-842.	6.4	49
8	Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 204-215.	1.9	39
9	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. <i>Frontiers in Pediatrics</i> , 2020, 8, 342.	1.9	35
10	Pulmonary arterial hypertension: Basic knowledge for clinicians. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 550-561.	1.6	34
11	Distinct right ventricle remodeling in response to pressure overload in the rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H85-H95.	3.2	33
12	Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2016, 109, 44-54.	3.8	33
13	M-mode and Doppler echocardiographic reference values for male New Zealand white rabbits. <i>American Journal of Veterinary Research</i> , 2006, 67, 1725-1729.	0.6	30
14	ET-1 increases distensibility of acutely loaded myocardium: a novel ET <sub>A</sub> and Na <sup>+</sup> /H <sup>+</sup> exchanger-mediated effect. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 284, H1332-H1339.	3.2	26
15	Urocortin 2 in cardiovascular health and disease. <i>Drug Discovery Today</i> , 2015, 20, 906-914.	6.4	25
16	Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H1194-H1199.	3.2	22
17	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. <i>Cardiovascular Research</i> , 2021, 117, 2474-2488.	3.8	20
18	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2018, 114, 1165-1177.	3.8	19

#	ARTICLE	IF	CITATIONS
19	Angiotensin-(1 $\alpha$ 7) Modulates Angiotensin II-Induced Vasoconstriction in Human Mammary Artery. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 513-522.	2.6	18
20	Novel insights into the role of urotensin II in cardiovascular disease. <i>Drug Discovery Today</i> , 2019, 24, 2170-2180.	6.4	18
21	A Western-Type Diet Attenuates Pulmonary Hypertension with Heart Failure and Cardiac Cachexia in Rats. <i>Journal of Nutrition</i> , 2011, 141, 1954-1960.	2.9	17
22	Intraventricular pressure gradients throughout the cardiac cycle: effects of ischaemia and modulation by afterload. <i>Experimental Physiology</i> , 2013, 98, 149-160.	2.0	16
23	Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 376, 107-115.	3.0	13
24	Neuregulin $\alpha$ 1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 255-265.	1.9	11
25	Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension. <i>Biomolecules</i> , 2022, 12, 484.	4.0	11
26	Left intraventricular diastolic and systolic pressure gradients. <i>Experimental Biology and Medicine</i> , 2011, 236, 1364-1372.	2.4	10
27	Myocardial effects of endothelin-1. <i>Revista Portuguesa De Cardiologia</i> , 2008, 27, 925-51.	0.5	9
28	Effects of adrenomedullin on systolic and diastolic myocardial function. <i>Peptides</i> , 2009, 30, 796-802.	2.4	8
29	An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	8
30	Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 599-613.	2.6	7
31	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. <i>European Journal of Pharmacology</i> , 2020, 889, 173658.	3.5	7
32	Impaired response to ET(B) receptor stimulation in heart failure: functional evidence of endocardial endothelial dysfunction?. <i>Experimental Biology and Medicine</i> , 2006, 231, 893-8.	2.4	6
33	Improvement in left intraventricular pressure gradients after aortic valve replacement in aortic stenosis patients. <i>Experimental Physiology</i> , 2017, 102, 411-421.	2.0	5
34	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	2.6	5
35	Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension. <i>Current Problems in Cardiology</i> , 2022, 47, 100860.	2.4	3
36	Obligatory role of the endocardial endothelium in the increase of myocardial distensibility induced by endothelin-1. <i>Experimental Biology and Medicine</i> , 2006, 231, 876-81.	2.4	3

#	ARTICLE	IF	CITATIONS
37	Effects of urocortin-2 on cellular Ca <sup>2+</sup> homeostasis in right heart failure induced by pulmonary artery hypertension. , 2018, , .		1
38	Cardiotoxicity of Cancer Chemotherapyâ€œRecent Developments. , 2016, , 36-83.		1
39	Urocortins as biomarkers in cardiovascular disease. Clinical Science, 2022, 136, 1-14.	4.3	1
40	Neuregulin-1 modulates right ventricle cardiomyocyte function in pulmonary arterial hypertension. European Heart Journal, 2013, 34, P5029-P5029.	2.2	0
41	P505Neuregulin-1 ameliorates right ventricular diastolic dysfunction in pulmonary arterial hypertension. Cardiovascular Research, 2014, 103, S92.4-S92.	3.8	0
42	P755Molecular mechanisms underlying the beneficial effects of neuregulin-1 in pulmonary arterial hypertension. Cardiovascular Research, 2014, 103, S138.3-S138.	3.8	0
43	149 The acute decrease of myocardial stiffness induced by beta-adrenergic stimulation is independent of the endocardial endothelium and prostaglandins release. European Journal of Heart Failure, Supplement, 2007, 6, 38-38.	0.0	0
44	154 Urocortin 2 acutely decreases myocardial stiffness. European Journal of Heart Failure, Supplement, 2007, 6, 39-40.	0.0	0
45	55 Time dependent increase in myocardial distensibility after an acute preload elevation. European Journal of Heart Failure, Supplement, 2007, 6, 9-9.	0.0	0
46	Abstract 5956: Modulation of Urocortin 2 Contractile Effects by Endocardial Endothelium. Circulation, 2008, 118, .	1.6	0
47	Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. , 2018, , .		0
48	Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. , 2018, , .		0